Adheren provides the most general, efficient biotechnology available for the attachment of any living cell to any desired analysis and diagnostic platform. Our solutions are used by academic, government, biotech, and pharmaceutical research laboratories for cellular analysis, molecular diagnostics, and drug screening applications. Relative to other cell immobilization methods, our technology produces higher binding efficiency, stronger adhesion, and decreased activation of intracellular signaling pathways.
Caribou Biosciences is dedicated to developing novel life science research tools. We utilize the unique nucleic acid binding and cleaving properties of proteins found in the prokaryotic immune system called CRISPR to develop new platform technologies. We are currently developing tools for affinity tagging and purifying RNAs and RNA-protein complexes and for site-specific genome engineering.
EndoOrthopaedics has developed a novel fracture fixation platform to repair bones that have been broken adjacent to a joint. Our technology is based on a system of modular fixation elements featuring an intuitive method of surgical deployment. It requires substantially fewer steps for implantation, and much greater capability compared to presently available devices.
Silicon BioDevices is a biotech semiconductor company operating at the interface between life sciences and information technology. By leveraging the high functionality and low cost of integrated circuit technology, Silicon BioDevices is able to bring novel digital solutions to bear on complex and persistent medical problems.
Valitor, Inc. is a drug optimization company. Using our core technologies, we can chemically modify existing, protein-based drug compounds to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Our mission is to develop advanced biologics therapies that will considerably lower the costs associated our target diseases by reducing the amount of clinical effort that is required for effective treatment.
Omniox is a biotechnology company commercializing a revolutionary and proprietary oxygen delivery technology for a broad range of clinical indications in cancer, surgical and cardiovascular markets. Omniox’s biotherapeutic platform was developed at the University of California, Berkeley by a team of outstanding scientists who have engineered a new class of oxygen delivery vehicles with properties that can be exploited for a range of clinical applications. Omniox was founded to translate these vehicles into focused therapeutics.
uBiome is a platform to enable citizen scientists to use microbiome samples to understand their health.
While the sequencing of the human genome has provided invaluable knowledge, it is very difficult to change our own genetic makeup. uBiome will ultimately empower participants to manage their microbiomes to improve their health as well as make important scientific discoveries for humanity.
By joining uBiome, you can explore your own microbiome as well as take part in the process of scientific discovery.
ZoneOne Pharma is focused on developing liposomal chelator therapeutics and also performs contract formulation of liposome drugs.
Aquinox Pharmaceuticals is a private, venture-backed pharmaceutical company committed to the discovery, development and commercialization of novel and targeted small molecule therapeutics for the treatment of inflammatory disease and cancer. Aquinox remains the world leader in the discovery and development of first-in-class therapeutics targeting SH2-containing inositol-5-prime-phosphatase (“SHIP1”) for the treatment of inflammatory disease. Its lead clinical candidate, AQX-1125, is a highly active and selective small molecule allosteric activator of SHIP1 suitable for once-daily oral dosing as a pill. AQX-1125 is currently being investigated in two Phase IIa proof-of- concept studies that the company anticipates completing in 2012.
BioMark Technologies is a Canadian based medical diagnostic technology company developing an inexpensive and noninvasive screening test for cancer that detects intracellular enzyme activity. This technology is small-molecule-based versus proteomics-based, which reduces complexity and lowers cost to the health care/delivery industry. The technology, apart from being a screening test, has potential to monitor therapeutic response or failure thereof. The innovation is reliable, cost effective, reproducible and can be made available/accessible to remote populations economically. Additional applications using the technology platform are being developed.
Clinisys EMR is a Canadian health informatics company offering software and services to the healthcare industry. Its flagship product is a robust, secure, and scalable web-based Clinical Intelligence Electronic Medical Record (EMR) system. The software is designed for small and mid-sized medical clinics, laboratories, individual physicians, specialists, and other healthcare workers, providing them with easy access to patient records including medical history, prescription history, lab results, referrals and other related data. Going beyond patient record management for its end-users, Clinisys also delivers patient-level, practice-level, and system-wide clinical intelligence.
Precision NanoSystems has developed proprietary microfluidic devices for the simple, rapid, reproducible and cost-effective manufacture of next-generation lipid nanoparticles (LNP). LNP can be engineered to package and deliver a wide range of bioactive agents to cells and tissues in the body, including conventional or biologic drugs for disease treatment and imaging agents for disease diagnosis. PNI has developed the automated NanoAssembly instrument to allow Pharma and Biotech companies to easily develop and manufacture novel LNPbased therapeutics and diagnostics. PNI seeks partnering opportunities with pharmaceutical and diagnostic companies to enable the development of LNP-based therapeutics and diagnostic imaging agents.
TeselaGen builds enabling technologies that allow synthetic biologists to accelerate the construction of microbial factories for producing medications, diverse chemicals and novel materials, converting plant material into biofuel, and breaking down toxic waste. Our modular software tools are designed to encompass the entire design/build/test cycle of the forward engineering approach to synthetic biology.
Accurus is a young biomedical contract research company based in the San Francisco Bay Area. The company has expertise in recombinant protein expression, stable cell line generation and hybridoma antibody technologies. Currently Accurus provides services in recombinant protein and antibody production, stable cell line generation, membrane receptor protein production and preparation, and hybridoma antibody scale-up, as well as other project support.
Flamentera is focused on celiac disease and was co-founded by Professor Chaitan Khosla at Stanford University. The company is developing non-invasive tests for lifelong monitoring of celiac patients.
Genicell performs early stage in-vitro drug permeability screening of the blood-brain barrier for the pharmaceutical industry. The company, founded by a small team of passionate biotech engineers, is developing clinically translatable testing platform.
Kiverdi upgrades waste carbon into oil using a proprietary bioprocess that is robust against impurities and economical at small scales. Kiverdi’s cutting-edge Carbon EngineeringTM platform uses engineered, gas-consuming microbes that thrive under ambient conditions without the aide of light and can be grown on diverse feedstocks including landfill and agricultural waste—enabling the low-cost conversion of waste carbon into high value products by design. From oil for drop-in fuels to custom oil-based consumer chemicals and biomaterials, Kiverdi makes oil for everyday products.
Lypro Biosciences is a therapeutic development company whose proprietary drug delivery nanotechnology increases the solubility and bioavailability of hydrophobic drugs and facilitates drug targeting to specific receptor(s).
Nano Precision Medical
Ablexis develops animal systems for accurate prediction in human drug with bacterial artificial chromosome based genome engineering technology. Its technology platform also provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. In addition, the company’s technology is used for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations.
Allopartis is a biofuel industry company focused on providing technologies for improving the efficiency and decreasing the cost for converting sustainable biomass products into clean-burning fuels.
Carmot Therapeutics, Inc.
China Medical City
Delpor’s mission is to create the next generation of Drug Delivery Systems which will improve the clinical and commercial value of new and existing drugs and biopharmaceuticals.
Gemmus is a biotechnology company that is developing novel therapeutics for influenza and other infectious diseases.
GigaGen’s mission is to bring next-generation sequencing into clinical practice.
Jennerex Biotherapeutics is a private, clinical-stage biotherapeutics company focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors.
Medicus is an early-stage, venture-backed start-up company in the San Francisco Bay Area developing break-through polymer technology for biomedical applications. The polymer technology will help save lives and will provide improved quality of life to the patients.
Metafold Therapeutics, Inc.
Metafold is developing breakthrough medicines to improve beta-cell function and longevity for the treatment of diabetes mellitus type 2.
Moleculo is a Stanford spin-off developing a novel DNA sequencing method which delivers reads that longer and more accurate than any currently available technology — thus improving the efficiency and accuracy of many existing DNA sequencing applications and enabling a range of new applications. We recently closed our seed round and moved to the Mission Bay Innovation Center.
OptoRobotix is developing novel plug-and-play cell-sorting instruments and disposable “application kits” for life science research. They overcome fundamental limitations of conventional flourescence activated cell sorting “FACS” technology and thereby unlock large untapped markets.
Osprey is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases. The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.
Pathway Therapeutics is focused on the discovery and development of the next generation of novel, differentiated, selective inhibitors of PI3-kinase(PI3K) for the treatment of cancers and inflammatory diseases.
Refactored Materials manufactures high-value natural materials that cannot be economically extracted from nature. The initial product is dragline spider silk, adapted for large scale production and commercialization. Refactored Spider Silk has potential applications anywhere that stiffness, weight, and failure resistance are valued at a premium, which includes fuel efficient automobiles, high performance aerospace, and military products.
SeaChange uses new computational techniques to identify drugs that may be repurposed, typically for orphan and underserved diseases. SeaChange will run the computational calculations and analysis necessary to expand and test its portfolio of drug ‘off-target’ predictions, which will be validated in vitro by CRO and partnerships.
High-throughput, high-accuracy array-based resequencing.
Silver Creek is developing novel regenerative medicines with an initial focus on treating cardiovascular disease. Using principles of engineering and network biology, Silver Creek is pioneering an entirely new platform of biotherapeutics that can promote resilience and even regeneration of cardiac cells, while minimizing unwanted effects in other tissues.
Solidus provides high-throughput, chip-based toxicology assays. By creating miniaturized array of three-dimensional cell cultures on a chip and incorporating the effects of metabolism into the screen, the Solidus platform delivers toxicity results that are more predictive of human or animal toxicity than standard well-plate screens. The Solidus technology is used by cosmetic companies to replace animal testing in safety assessment and by pharmaceutical companies for early-stage toxicity screening of drug candidates.
Tunitas is poised to develop unique and precisely targeted protein therapeutics that will dramatically change the lives of allergy sufferers. With Tunitas’ proteins, patients receive a treatment regimen in their allergist’s office that will alter the natural course of their disease, providing a therapeutic option with long-lasting benefit.